Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053281 | 0.76 | MRGPRX4 (0.55) | MRGPRX4 | |
| SCHEMBL24792590 | 0.76 | MRGPRX4 (0.61) | HTR2CHTR2BMRGPRX4HTR6SLC6A4 | |
| SCHEMBL2410760 | 0.75 | HTR3A (0.62) | HTR2CHTR2BHTR6SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL4573020 | 0.74 | HTR3A (0.61) | HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22480899 | 0.74 | MRGPRX4 (0.54) | HTR2CHTR2BMRGPRX4HTR6SLC6A4 | |
| SCHEMBL2287675 | 0.73 | HTR2C (0.91) | HTR2CHTR2BHTR6SLC6A4 | |
| SCHEMBL2285747 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR6SLC6A4 | |
| SCHEMBL2285745 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR6SLC6A4 | |
| SCHEMBL2287598 | 0.73 | HTR2C (1.00) | HTR2CHTR2BHTR6SLC6A4 | |
| SCHEMBL2287668 | 0.73 | HTR2C (0.91) | HTR2CHTR2BHTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | HTR2C 232/4885HTR2B 199/4885MRGPRX4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.